

**Question for written answer E-005336/2021
to the Commission**

Rule 138

Tanja Fajon (S&D), Marian-Jean Marinescu (PPE)

Subject: Radioligand therapies and the preparedness of EU hospital infrastructure

Following on from our written question of 1 March 2021 on increasing the preparedness of EU hospital infrastructure, and the Commission's answer of 28 May 2021, we would like to ask some follow-up questions.

In its answer, the Commission stated that there are several upcoming plans to address hospital preparedness, including measures to improve radiation quality and safety in nuclear medicine under the Strategic Agenda for Medical Ionising Radiation Applications (the SAMIRA action plan). As this strategic plan aims to reduce inequalities, the need to ensure fair access to high-quality and nuclear technologies in the medical field in all Member States should be further reiterated.

The Commission is also aiming to foster interaction with stakeholders in the nuclear medicine field in order to strengthen the role of comprehensive cancer centres.

1. How will the Commission make sure that the objective of improving workforce availability, radiation safety culture, education and training under the SAMIRA action plan will be fairly distributed and promoted within and between Member States?
2. Following the creation of the EU Network of National Comprehensive Cancer Centres, does the Commission plan to continue engaging with relevant stakeholders and collaborate with them to assess the overall functioning of these centres on a regular basis?